PMID: 11314934Apr 21, 2001Paper

Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma

Annals of Surgical Oncology
G J TsiouliasD L Morton

Abstract

TA90 is a tumor-associated 90-kD glycoprotein antigen expressed on most melanoma cells, including those of CancerVax, a polyvalent allogeneic whole-cell vaccine. Previous studies have shown that a TA90 antigen-antibody immune complex (IC) in the serum of patients with melanoma is a marker of subclinical tumor burden and a strong prognostic factor. We hypothesized that the induction of TA90-IC during postoperative adjuvant CancerVax therapy might indicate vaccine-mediated immune destruction of subclinical melanoma cells with release of TA90, and thereby serve as a surrogate marker of vaccine efficacy. From 1993 to 1997, 219 melanoma patients were enrolled in a prospective phase II trial of CancerVax plus bacille Calmette-Guerin (BCG) after complete tumor resection. Coded serum samples were prospectively collected and analyzed for TA90-IC before and 2, 4, 8, 12, and 16 weeks after initiation of CancerVax therapy. TA90-IC seroconverters were those patients whose negative TA90-IC values (< .410) became positive (> or = .410) after initiation of CancerVax treatment. Before CancerVax therapy, 51 patients had positive TA90-IC values and 168 patients had negative TA90-IC values. During CancerVax treatment, all 51 positive patients rema...Continue Reading

References

Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·D M EuhusD L Morton
Jan 15, 1995·Cancer·A Barth, D L Morton
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E TartourW H Fridman
Jul 1, 1996·CA: a Cancer Journal for Clinicians·D L Morton, A Barth
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E C HsuehD L Morton

❮ Previous
Next ❯

Citations

May 30, 2002·Annals of Surgery·Rebekah R WhiteHilliard F Seigler
May 3, 2014·Current Treatment Options in Oncology·Sarah A WeissAnna C Pavlick
May 19, 2012·Seminars in Oncology·Howard L Kaufman
Aug 14, 2019·Applied Microbiology and Biotechnology·Martha Lucia Ruiz BenitezFabiana Kömmling Seixas
Apr 21, 2001·Annals of Surgical Oncology·H K LyerlyT M Clay
Jul 31, 2007·Cancer Investigation·Mark B FariesDonald L Morton
Jul 25, 2003·Ophthalmic Plastic and Reconstructive Surgery·Michael BaroodyJohn B Holds
Dec 10, 2003·Expert Opinion on Emerging Drugs·L G Durrant, I Spendlove
May 1, 2010·Oncology Letters·Mays Al-ShaerChris Papageorgio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

The European Journal of Surgery = Acta Chirurgica
G E MessarisP C Karakousis
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
Michael J Leveridge, Michael A S Jewett
Expert Review of Anticancer Therapy
Eyad ElkordRobert E Hawkins
Clinical & Developmental Immunology
Momoe Itsumi, Katsunori Tatsugami
© 2021 Meta ULC. All rights reserved